| P50 | author | Peter C. Hayes | Q89415621 |
| | Sharon J Hutchinson | Q90689013 |
| | John F. Dillon | Q38545342 |
| | Adrian J. Stanley | Q55232560 |
| P2093 | author name string | Peter R Mills | |
| | Scott A McDonald | |
| | David J Goldberg | |
| | Andrew Fraser | |
| | Stephen Barclay | |
| | Hamish A Innes | |
| | Judith Morris | |
| | Hepatitis C Clinical Database Monitoring Committee | |
| | Elaine Cadzow | |
| P2860 | cites work | Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies | Q28748551 |
| | Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 |
| | Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. | Q31040495 |
| | Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. | Q33865320 |
| | Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women | Q34520930 |
| | Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression | Q34787367 |
| | Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. | Q35768976 |
| | The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan | Q36185899 |
| | Estimating the population attributable risk for multiple risk factors using case-control data | Q36499362 |
| | Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. | Q36754880 |
| | Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease | Q37794163 |
| | Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland | Q37995449 |
| | Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study | Q38451670 |
| | When can odds ratios mislead? | Q41742782 |
| | Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion | Q42633467 |
| | Population-based risk factors and resource utilization for HCC: US perspective | Q42953743 |
| | Factors associated with cirrhosis development in chronic hepatitis C patients from an area of low prevalence | Q42986748 |
| | Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. | Q42988446 |
| | Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. | Q42989119 |
| | Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection | Q42992687 |
| | Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users | Q43000196 |
| | Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. | Q43000459 |
| | Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). | Q43039935 |
| | Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always | Q43040631 |
| | Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. | Q43685787 |
| | Market uptake of new antiviral drugs for the treatment of hepatitis C. | Q44557658 |
| | Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum | Q44562896 |
| | Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus | Q44781061 |
| | Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. | Q44962636 |
| | Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations | Q45363548 |
| | Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis | Q45422773 |
| | Impact of alcohol on the histological and clinical progression of hepatitis C infection. | Q50867355 |
| | Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. | Q51506507 |
| | Alcoholic liver disease. | Q51764048 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver cirrhosis | Q147778 |
| | hepatitis C | Q154869 |
| | Hepatitis C virus | Q708693 |
| | chronic hepatitis C | Q55779873 |
| P304 | page(s) | 451-460 | |
| P577 | publication date | 2013-01-08 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness | |
| P478 | volume | 57 | |